8.7 Bone Loss During Cancer Treatment
Key Takeaways
Treatment-specific oncology guidance may support bone protection at a T-score above −2.5. The BMD category and the treatment decision answer different questions.
The U.S. Prolia label includes bone mass indications in selected high-risk patients on adjuvant aromatase inhibitor therapy or ADT for nonmetastatic prostate cancer.
Oncology regimens for preventing skeletal-related events in myeloma or documented bone metastases have a different purpose and dosing.
Choose monitoring intervals according to the applicable guideline, clinical risk and expected change.
Identify the treatment and the clinical purpose
Cancer treatment can add fracture risk to age, previous fractures and other baseline factors. Aromatase inhibitors such as anastrozole, letrozole and exemestane reduce estrogen synthesis. Ovarian suppression, oophorectomy and chemotherapy-induced ovarian failure can also reduce estrogen exposure. In prostate cancer, androgen deprivation therapy (ADT) can reduce sex steroid support of bone. Ask what the patient is receiving, for how long, and whether there is known skeletal metastatic disease. Assess fracture risk and any focal skeletal symptoms in parallel.
U.S. aromatase inhibitor labels warn about reductions in bone mineral density (BMD). The Femara and Arimidex labels advise considering BMD monitoring. For adjuvant Aromasin, the label calls for baseline densitometry in women with osteoporosis or at risk and monitoring for BMD loss. These warnings inform the clinical assessment. They do not share a single drug-specific threshold for starting an antiresorptive.
Compare recommendations in the correct setting
| Source and setting | Practical interpretation |
|---|---|
| ASCO 2019, adults with nonmetastatic cancer | Assess clinical fracture risk and obtain DXA when substantial risk is present. For the population specified by the guideline, osteoporosis-range BMD at eligible axial sites or increased risk, such as U.S. FRAX MOF ≥20% or hip ≥3%, can support osteoporosis-dose therapy. Consider expected rapid loss and clinical context. |
| 2025 international joint position on aromatase inhibitor-associated bone loss | Evaluate BMD and clinical risk in women on relevant breast cancer endocrine therapy. The algorithm supports an antiresorptive for a T-score below −2.0 or qualifying combinations of risk factors. With T-score above −2.0 and no additional risks, monitor risk and BMD at one- to two-year intervals. |
| ASCO-endorsed 2020 prostate cancer guidance | Baseline DXA is encouraged before ADT. For a man at high fracture risk receiving ADT for nonmetastatic prostate cancer, osteoporosis-dose denosumab can be considered. A bisphosphonate is an option when denosumab is unsuitable or unavailable. |
ASCO's general nonmetastatic cancer guideline advises BMD testing about every two years for patients on bone-loss-inducing therapy or near a treatment threshold, and sooner when medically necessary. Cancer Care Ontario updated its prostate cancer recommendations in 2025 and discusses osteoporosis fracture prevention in high-risk men on ADT with or without bone metastases. That Canadian recommendation does not broaden the U.S. Prolia indication. These schedules differ from the ISCD follow-up position, which individualizes timing based on the clinical purpose and rate of change. Use a comparable site and technique and the applicable least significant change (LSC). A statistically significant change deserves review. Its significance alone does not make it a universal drug-start rule.
For example, a 63-year-old postmenopausal woman starting letrozole for nonmetastatic breast cancer has a valid femoral neck T-score of −2.2. Her T-score falls in the low bone mass range under the usual adult densitometric classification. The 2025 joint AI-specific algorithm supports considering a bone-protective agent even at this score. Record the guideline and treatment context rather than reporting a DXA diagnosis of osteoporosis from that score.
Distinguish fracture prevention from cancer-related skeletal events
The U.S. Prolia label includes increasing bone mass in women at high fracture risk receiving adjuvant aromatase inhibitor therapy for breast cancer and in men at high fracture risk receiving ADT for nonmetastatic prostate cancer. The labeled dose is 60 mg subcutaneously every six months. In the ADT study, the label also reports a reduction in vertebral fractures. A treatment recommendation for a bisphosphonate in a cancer guideline does not create the same FDA indication as Prolia. Reclast has separate approved osteoporosis and other bone disease indications.
Known skeletal metastases introduce different outcomes and regimens. For example, U.S. Xgeva labeling lists prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors at 120 mg subcutaneously every four weeks. Oncology zoledronic acid labeling also addresses myeloma and documented bone metastases with standard antineoplastic therapy. The oncology regimen, renal assessment and purpose are distinct from osteoporosis care. Review the oncology plan if the same active ingredient appears under more than one brand name.
ASCO nonmetastatic cancer guideline · 2025 AI joint position statement · ASCO prostate cancer endorsement · Cancer Care Ontario 2025 update · Femara label · Arimidex label · Aromasin label · Prolia label · Reclast label · Xgeva label · Oncology zoledronic acid label
A 63-year-old postmenopausal woman starts letrozole for nonmetastatic breast cancer. Her lowest valid T-score is −2.2 at the femoral neck. Which interpretation is supported by the 2025 joint position on aromatase inhibitor-associated bone loss?
Letrozole use changes the densitometric diagnosis from low bone mass to osteoporosis.
No bone-protective therapy can be considered until the score reaches −2.5.
She has low bone mass by the usual classification, and the AI-specific algorithm supports considering a bone-protective agent.
She requires a metastatic skeletal-event regimen because she has a breast cancer diagnosis.
A man at high fracture risk is receiving androgen deprivation therapy for nonmetastatic prostate cancer. Which statement reflects a U.S. labeled indication?
Prolia can be used to increase bone mass at 60 mg subcutaneously every six months.
Xgeva must be used to prevent first bone metastases.
Reclast and Prolia have identical FDA indications specific to androgen deprivation therapy.
The U.S. Prolia bone mass indication requires documented bone metastases.
A patient with documented bone metastases from a solid tumor is prescribed denosumab to prevent skeletal-related events. Which U.S. labeled regimen matches this purpose?
Prolia 60 mg subcutaneously every six months.
Xgeva 120 mg subcutaneously every six months.
Xgeva 60 mg subcutaneously every four weeks.
Xgeva 120 mg subcutaneously every four weeks.
Sections you finish are checked off in the contents.